Cardinal will have to give up significant margin if they want to keep a sole source. Read the recent headlines with AAAP. They have Cardinal, Triad, Zevacor, and UPPI all to access product and dispense. The days of sole source are LONG gone and if Cardinal wants that they will have to pay. If they stay with Cardinal expect a deal in the next 6-10 months. Bottom line, the margins are going to go out of the roof soon.
CELG will recognize the value of this patent. They bought Abraxis and they had a similar technology. CLRB's technology will trump that of Abraxane. I don't think CELG will want to let someone else take their market share. Logical buyout play.
ASCO getting attention as the patent application technology with paclitaxel.
This weekend - ASCO
Next weekend - SNMMI
Next week - Investor Conf.
In the mean time the biospace is seeing the value of their patent. I expect a buyout sooner than later. Will see teens here imo.
no thanks. say right here with CLRB as they have 3 upcoming catalyst. ASCO this weekend, SNMMI next weekend, and Investor conf. next week. Will soon see the teens with CLRB.
Google Paclitaxel spend... in the billions!!
PDC chemotherapeutics through conjugation of non-targeted anti-cancer agents with the company’s novel delivery vehicle with the goal of improving therapeutic indices, enhancing product profiles and expanding potential indications through targeted cancer cell delivery of chemotherapeutic payloads
buyout at a minimum of 100 million market cap.